Authorizes certain reimbursement for travel. (BDR R-5)
Impact
The proposal represents a notable adjustment in the management of legislative travel reimbursements, allowing for a more flexible allocation of funds as legislators navigate the unpredictability of special sessions. By enabling the transfer of unused reimbursements, ACR2 seeks to ensure that legislators can adequately cover their travel expenses even when facing unexpected demands during special sessions. The resolution reinforces the idea that legislative duties may require additional financial consideration beyond regular sessions.
Summary
ACR2, or Assembly Concurrent Resolution No. 2, aims to authorize reimbursement for travel expenses for legislators during specific legislative sessions in Nevada. The resolution stipulates that any unused reimbursement amounts for travel that a legislator is authorized to utilize during the 83rd Session of the Nevada Legislature will be applied towards travel expenses incurred in any special session held between June 3, 2025, and November 3, 2026. This provision is intended to provide financial support to legislators who may exceed their reimbursement limits during special sessions.
Contention
While the bill generally aims to facilitate travel for legislators, potential contention could arise regarding how reimbursement limits are set and whether all legislators will have equitable access to these funds. Opponents may question the fairness of reallocating unused reimbursements, particularly if some legislators consistently exceed their limits while others do not. The resolution may spur debate about the financial implications for state budgets and the prioritization of legislative travel in comparison to other state expenditures.
Authorizes, under certain circumstances, the reimbursement of costs incurred by certain counties related to certain activities that are subject to the excise tax on live entertainment. (BDR 32-115)
Requires the Director of the Department of Health and Human Services to seek to establish certain rates of reimbursement under Medicaid for certain devices to treat epilepsy. (BDR S-571)